By PR Newswire, October 24, 2013, 09:18:00 AM EDT
Editor Note: For more information about this release, please scroll to bottom.
LONDON, October 24, 2013 /PRNewswire/ --
On Wednesday, October 23, 2013, all three indexes of the US equity market declined. The S&P 500 ended the day at 1,746.38, down 0.47%; the Dow Jones Industrial Average closed at 15,413.33, down 0.35%; and the NASDAQ Composite finished at 3,907.07, down 0.57%. Shares in the drugs - generic industry ended mostly on a higher note, even as the broader market edged lower. The major movers in the industry included Zoetis Inc. (NYSE:ZTS), AVANIR Pharmaceuticals Inc. (NASDAQ:AVNR), Actavis plc (NYSE:ACT), and Salix Pharmaceuticals Ltd (NASDAQ:SLXP). AAAResearchReports.com free coverage on ZTS, AVNR, ACT, and SLXP is available upon registration at:
Zoetis Inc.'s stock edged higher on Wednesday, closing at $32.60, up 0.28%, after oscillating between $32.48 and $32.90 during the trading session. A total of 2.82 million shares were traded, which is below the daily average volume of 4.45 million. The company's shares have gained 8.45% in the previous three months and 3.23% in the last one month, outperforming the S&P 500, which has advanced 3.19% and 2.62% during the respective periods. Moreover, Zoetis Inc.'s stock is trading above its 50-day moving average of $31.16. Download free technical research on ZTS by signing up at:
Shares in AVANIR Pharmaceuticals Inc. rallied on Wednesday, vacillating between $4.46 and $4.72 before finishing the day 4.89% higher. A total of 2.66 million shares were traded, which is below the daily average volume of 3.02 million. AVANIR Pharmaceuticals Inc.'s shares have advanced 10.28% in the last one month and 4.66% in the previous three trading sessions, outperforming the S&P 500, which has advanced 2.62% and 0.11% during the respective periods. Furthermore, the company's stock is trading above its 200-day moving averages of $3.80. Register now and get access to free analysis on AVNR at:
On Wednesday, Actavis PLC's stock declined to close at $145.75, down 0.78% from the previous day's closing price of $146.89. The company's shares vacillated between $143.71 and $146.12 during the trading session. A total of 1.68 million shares were traded, which is above the daily average volume of 1.41 million. Despite Wednesday's pullback, the company's shares have gained 15.30% in the previous three months and 5.16% in the last one month, outperforming the S&P 500, which has gained 3.19% and 2.62% during the respective periods. Further, Actavis PLC's stock is trading above its 50-day and 200-day moving averages of $139.01 and $114.70, respectively. Sign up and read our complimentary report on ACT at:
Salix Pharmaceuticals Ltd's shares ended the day at $73.00, up 0.01%, after fluctuating between $71.40 and $73.35 during the trading session. A total of 0.50 million shares were traded, which is below the daily average volume of 0.79 million. The company's shares have gained 5.32% in the last three months and 9.49% in the previous one month, compared to a gain of 3.19% and 2.62% in the S&P 500 during the respective periods. Furthermore, Salix Pharmaceuticals Ltd's stock is trading above its 50-day and 200-day moving averages of $68.36 and $59.55, respectively. The free report on SLXP can be downloaded by signing up now at:
This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports